AS Coates

1.3k total citations · 1 hit paper
20 papers, 896 citations indexed

About

AS Coates is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, AS Coates has authored 20 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cancer Research, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Genetics. Recurrent topics in AS Coates's work include Breast Cancer Treatment Studies (14 papers), Estrogen and related hormone effects (10 papers) and Advanced Breast Cancer Therapies (8 papers). AS Coates is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Estrogen and related hormone effects (10 papers) and Advanced Breast Cancer Therapies (8 papers). AS Coates collaborates with scholars based in Switzerland, Australia and Belgium. AS Coates's co-authors include Anthony Howell, JF Forbes, Rob Edwards, J Cuzick, T.J. Powles, Simon Cawthorn, Michael Baum, Richard Kefford, Roger R. Reddel and Justin Grant and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

AS Coates

19 papers receiving 863 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

2002 533 citations J Cuzick, JF Forbes et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
AS Coates Switzerland	8	493	479	356	154	88	20	896
K. M. Rowland United States	10	348 0.7×	217 0.5×	54 0.2×	161 1.0×	89 1.0×	26	740
Julian Peto United Kingdom	13	523 1.1×	231 0.5×	169 0.5×	91 0.6×	462 5.3×	15	1.1k
Jean Abraham United Kingdom	16	398 0.8×	224 0.5×	236 0.7×	95 0.6×	214 2.4×	40	896
S Rotstein Sweden	13	341 0.7×	195 0.4×	387 1.1×	76 0.5×	74 0.8×	34	752
Kexin Meng China	14	161 0.3×	54 0.1×	155 0.4×	49 0.3×	210 2.4×	31	584
Craig Luccarini United Kingdom	13	225 0.5×	296 0.6×	164 0.5×	141 0.9×	435 4.9×	23	948
Riikka Huovinen Finland	17	659 1.3×	192 0.4×	311 0.9×	262 1.7×	250 2.8×	46	1.2k
Pei‐Ei Wu Taiwan	20	325 0.7×	332 0.7×	340 1.0×	67 0.4×	905 10.3×	32	1.4k
S. Gertler Canada	16	909 1.8×	600 1.3×	364 1.0×	513 3.3×	278 3.2×	37	1.5k
Peggy Wan United States	15	377 0.8×	325 0.7×	140 0.4×	212 1.4×	102 1.2×	22	971

Countries citing papers authored by AS Coates

Since Specialization

Citations

This map shows the geographic impact of AS Coates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AS Coates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AS Coates more than expected).

Fields of papers citing papers by AS Coates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AS Coates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AS Coates. The network helps show where AS Coates may publish in the future.

Co-authorship network of co-authors of AS Coates

This figure shows the co-authorship network connecting the top 25 collaborators of AS Coates. A scholar is included among the top collaborators of AS Coates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AS Coates. AS Coates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ribi, Karin, Wenjie Luo, Marco Colleoni, et al.. (2018). Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-reported symptoms and quality of life. Cancer Research. 78(4_Supplement). P5–18.

Pagani, Olivia, MM Regan, Marco Colleoni, et al.. (2018). Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. Cancer Research. 78(4_Supplement). GS4–2. 3 indexed citations

Galimberti, V., Giuseppe Viale, Paolo Veronesi, et al.. (2018). Abstract GS5-02: Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial. Cancer Research. 78(4_Supplement). GS5–2. 1 indexed citations

Regan, MM, Olivia Pagani, K.N. Price, et al.. (2017). Abstract OT3-02-03: Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer. Cancer Research. 77(4_Supplement). OT3–2. 1 indexed citations

Huober, J., Jian Wu, Anita Giobbie‐Hurder, et al.. (2011). Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.. Journal of Clinical Oncology. 29(15_suppl). 522–522. 6 indexed citations

Bouzyk, Mark, Kathryn P. Gray, Meredith M. Regan, et al.. (2011). ESR1 and ESR2 polymorphisms in BIG 1−98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1002–1002. 1 indexed citations

Huober, Jens, Beat Thürlimann, Meredith M. Regan, et al.. (2010). Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.. Journal of Clinical Oncology. 28(15_suppl). 630–630. 4 indexed citations

Metzger, Otto, Zijie Sun, Giuseppe Viale, et al.. (2010). Abstract P5-13-01: Patterns of Breast Cancer Relapse According to Breast Cancer Subtypes in Lymph Node-Negative Breast Cancer — Results from International Breast Cancer Study Group Trials VIII and IX. Cancer Research. 70(24_Supplement). P5–13. 1 indexed citations

Viale, Giuseppe, MM Regan, Patrizia Dell’Orto, et al.. (2009). Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.. Cancer Research. 69(24_Supplement). 76–76. 12 indexed citations

10.

Mouridsen, H.T., Anita Giobbie‐Hurder, L. Mauriac, et al.. (2009). BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.. Cancer Research. 69(2_Supplement). 13–13. 30 indexed citations

11.

Crivellari, Diana, Zijie Sun, AS Coates, et al.. (2007). Aromatase inhibitors (AI) for elderly patients: Efficacy, compliance and safety according to patient age in the BIG 1–98 trial. Journal of Clinical Oncology. 25(18_suppl). 9033–9033. 5 indexed citations

12.

Bernhard, Jürg, David Zahrieh, AS Coates, et al.. (2004). Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. British Journal of Cancer. 91(11). 1893–1901. 21 indexed citations

13.

Colleoni, Marco, Shari Gelber, Richard A. Snyder, et al.. (2004). Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13–93. Journal of Clinical Oncology. 22(14_suppl). 532–532. 2 indexed citations

14.

Cuzick, J, JF Forbes, Rob Edwards, et al.. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet. 360(9336). 817–824. 533 indexed citations breakdown →

15.

Bernhard, Jürg, Christoph Hürny, AS Coates, et al.. (1998). Factors affecting baseline quality of life in two international adjuvant breast cancer trials. British Journal of Cancer. 78(5). 686–693. 33 indexed citations

16.

Jonat, W., M. Kaufmann, R.W. Blamey, et al.. (1995). A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. European Journal of Cancer. 31(2). 137–142. 67 indexed citations

17.

Jonat, W., M. Kaufmann, R.W. Blamey, et al.. (1993). Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only. The Breast. 2(3). 203–204. 2 indexed citations

18.

Elliott, Perry, M. Tattersall, Malcolm Coppleson, et al.. (1989). Changing character of cervical cancer in young women. International Journal of Gynecology & Obstetrics. 30(1). 79–79. 14 indexed citations

19.

Woods, R., et al.. (1987). Chemotherapy of adult soft tissue sarcoma with combination of doxorubicin and methotrexate.. PubMed. 71(11). 1087–8. 1 indexed citations

20.

Reddel, Roger R., et al.. (1982). Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.. PubMed. 66(1). 19–23. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact